Summit Therapeutics (SMMT)
(Delayed Data from NSDQ)
$21.10 USD
+0.21 (1.01%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $20.86 -0.24 (-1.14%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.10 USD
+0.21 (1.01%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $20.86 -0.24 (-1.14%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Zacks News
Orexigen (OREX) Q2 Loss Narrows, Contrave Sales Impress
by Zacks Equity Research
Orexigen Therapeutics (OREX) reported adjusted loss of $1.82 per share in the second quarter of 2017, which was narrower than the Zacks Consensus Estimate. The company is focused on increasing the reach of Contrave.
Endocyte (ECYT) Stock Up Despite Wider-than-Expected Q2 Loss
by Zacks Equity Research
Endocyte (ECYT) second quarter loss was wider than expected. The company has announced restructuring initiatives to shift its pipeline focus to CAR-T cell platform.
Achillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update
by Zacks Equity Research
Achillion Pharmaceuticals (ACHN) second-quarter loss was in-line with estimates. The company's shares surged almost 28% in after-market trading on positive pipeline results.
Zoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View
by Zacks Equity Research
Zoetis (ZTS) reported impressive second-quarter results beating on both counts. The new launches and expansion of market for major products helped revenue growth.
Endo (ENDP) Beats Q2 Earnings & Sales, 2017 Guidance Lowered
by Zacks Equity Research
Endo (ENDP) beat second-quarter 2017 earnings and sales. However, revenues were down on a year over year basis due to generic competition adversely impacting the branded established products portfolio.
Arena Pharmaceuticals (ARNA) Q2 Loss Wider than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reported another quarter of lackluster Belviq sales. However, the company is expected to advance ralinpeg in phase III study soon based on positive phase II study results.
Ironwood (IRWD) Q2 Loss Widens, Revenues Miss, Stock Up
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) second-quarter results were dismal, missing sales and earnings estimates.
Spectrum (SPPI) Q2 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Spectrum Pharmaceuticals. (SPPI) reported narrower than expected sales and also beat sales expectations. The shares of the company were up due to positive pipeline updates.
Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View
by Zacks Equity Research
Shire plc (SHPG) product sales soared in the second quarter on the back of legacy Baxalta sales. However, generic competition is expected to negatively impact full year revenues.
Zacks.com featured highlights: Summit Therapeutics, Commercial Vehicle Group, DragonWave, Townsquare Media and CONSOL Energy
by Zacks Equity Research
Zacks.com featured highlights: Summit Therapeutics, Commercial Vehicle Group, DragonWave, Townsquare Media and CONSOL Energy
Sarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View
by Zacks Equity Research
Increase in Exondys 51 sales led Sarepta (SRPT) to post a narrower-than-expected loss in the second quarter of 2017.
Can Summit Therapeutics (SMMT) Run Higher on Strong Earnings Estimate Revisions?
by Zacks Equity Research
Summit Therapeutics (SMMT) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.
Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017
by Zacks Equity Research
We issued an updated research report on Cambridge, MA-based Sarepta Therapeutics, Inc. (SRPT) on Jun 28.
Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop
by Zacks Equity Research
Biotech major, Amgen, Inc. (AMGN) presented detailed results from the phase III cardiovascular outcomes study (FOURIER) on its PCSK9 inhibitor, Repatha.
Glaxo Files for Label Expansion of Influenza Vaccine in US
by Kinjel Shah
GlaxoSmithKline plc (GSK) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA seeking approval to expand the label of Fluarix Quadrivalent ??? an influenza vaccine - for infants six months or older.
Sarepta's DMD Drug Launch Slow; What's in Store for 2017?
by Zacks Equity Research
We issued an updated research report on Sarepta Therapeutics, Inc. (SRPT) on Mar 9, 2016.
J&J Presents Positive Phase III Data on Psoriasis Candidate
by Zacks Equity Research
Johnson & Johnson (JNJ) announced positive data from two phase III studies evaluating its pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis.
Geron (GERN) Q4 Loss Narrows; Focus Remains on Imetelstat
by Zacks Equity Research
Geron Corporation (GERN) reported a loss of 5 cents per share in the fourth quarter of 2016, flat year over year but narrower than the Zacks Consensus Estimate of a loss of 6 cents.
Kite Pharma (KITE) Posts Q4 Loss; Up on Positive Cancer Data
by Zacks Equity Research
Kite Pharma, Inc. (KITE) reported narrower-than-expected loss in the fourth quarter of 2016.
BioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) reported a loss of 37 cents per share in the fourth quarter of 2016.
Clovis (CLVS) Q4 Loss Wider than Expected; Focus on Rubraca
by Zacks Equity Research
Clovis Oncology, Inc. (CLVS) reported fourth-quarter 2016 loss of $1.83 per share, wider than the Zacks Consensus Estimate of a loss of $1.65.
Ironwood (IRWD) Q4 Loss Narrower than Expected; Sales Top
by Zacks Equity Research
Ironwood Pharmaceuticals, Inc. (IRWD) reported an adjusted loss of 12 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 23 cents but slightly wider than the year-ago loss of 11 cents.
Express Scripts (ESRX) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Express Scripts Holding Company (ESRX), is scheduled to report fourth-quarter 2016 results on Feb 14 after market closes.
Will Q4 Earnings Hold a Surprise for DaVita (DVA) Stock?
by Zacks Equity Research
DaVita HealthCare Partners Inc. (DVA) is set to report fourth-quarter 2016 results after market close on Feb 9.
GNC Holdings (GNC) Q4 Earnings: A Surprise in the Cards?
by Zacks Equity Research
GNC Holdings, Inc. (GNC) -- a specialty retailer of health and nutrition related products -- is scheduled to report fourth-quarter 2016 financial results on Feb 16, before the opening bell.